X
<

Calumet Specialty Delayed Its 3Q17 Results, Stock Fell 8.3%

PART:
1 2 3
Part 3
Calumet Specialty Delayed Its 3Q17 Results, Stock Fell 8.3% PART 3 OF 3

Calumet Specialty Expects Lower Capital Spending in 2018

Reduced leverage

According to Calumet Specialty Products Partners (CLMT), its pro forma net debt-to-total capital ratio after selling the Superior refinery is 76%—down from 90% at the end of 2Q17. Calumet Specialty received a total consideration of $492 million for the sale. It included “the sale price of $435 million, and an additional $57 million for net working capital, inventories, and reimbursement of certain capital spending.”

Calumet Specialty Expects Lower Capital Spending in 2018

Interested in CLMT? Don't miss the next report.

Receive e-mail alerts for new research on CLMT

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Expected capital spending

According to Calumet, its fuels business is capital intensive. The company expected to spend nearly $100 million on the Superior refinery in 2018. The sale decreases the company’s exposure to the capital-intensive business.

“Our capital intensity decreases because our specialty facilities do not require the same level of turnaround and maintenance, as do our fuels refineries,” said Tim Go, Calumet Specialty’s CEO, in the company’s conference call.

Calumet Specialty Expects Lower Capital Spending in 2018

Calumet Specialty lowered its 2017 capital expenditure guidance from $110 million–$130 million to $85 million–$95 million.

It also provided a guidance of $80 million–$90 million of capital expenditures for 2018. The above graph shows Calumet Specialty’s capital expenditures in the last three years as well as the forecasts for 2017 and 2018.

Year-to-date performance

Calumet Specialty Products Partners stock has more than doubled in 2017. CVR Refining (CVRR) has risen nearly 18%, while the Alerian MLP ETF (AMLP) has fallen nearly 16% during the same period.

X

Please select a profession that best describes you: